Published • loading... • Updated
Europe Gives Green Light to Ocrelizumab, a Therapy for Children and Adolescents with Recurrent Multiple Sclerosis
Summary by informacion.es
5 Articles
5 Articles
The authorization allows to cover "a gap that existed for a long time in Europe", declared the director of the pharmaceutical Roche.
·Madrid, Spain
Read Full Article
informacion.es+3 Reposted by 3 other sources
Roche has announced that the European Commission has approved ocrelizumab, a commercial name 'Ocrevus', in the form of an intravenous infusion for the treatment of paediatric patients aged 10 years and older with recurrent forms of multiple sclerosis. A complex disease, with unpredictable outbreaks requiring hospital admission and acute treatments, forcing children to miss school and to miss social activities, in addition to being at risk of fut…
Coverage Details
Total News Sources5
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
